Study reveals a new method of chemotherapy relieves the pain of cancer patients

A French study opened the way for a protocol that makes chemotherapy for cancer patients simpler by adopting subcutaneous injections, instead of intravenous injections, if this method proves effective in humans after testing on animals.

Cancer treatment is often based on intravenous chemotherapy, which generates many health consequences and requires hospitalization for the patient.

However, a study conducted in France on animals and published by the "American Chemical Society" gave hope to make the procedure more simplified.

One possibility that she notes for facilitating treatment is the introduction of subcutaneous chemotherapy.

Resorting to this method, which is easier to implement and less inconvenience to the patient, is often not possible because the active components of the treatment tend to stagnate in the subcutaneous tissues and cause necrosis due to their high toxicity.

Scientists have come up with a new approach aimed at overcoming this obstacle, by attaching the low-soluble active ingredient "paclitaxel" widely used in chemotherapy to a polymer with strong hydro-compatibility. It passes quickly from the subcutaneous tissue into the bloodstream without causing toxicity at the site of injection.

During preclinical trials of this new chemotherapy in mice, the scientists found that it was more effective than the commercial formulation of the active ingredient (Taxol) given intravenously.

The lead author of the study, director of research at the French National Center for Scientific Research (CNRS), Julien Nicolas, told AFP that "chemotherapy has many logistical requirements (such as providing qualified staff, hospitalization, etc.), and a high cost", stressing that "the main benefit of this The new approach is to facilitate chemotherapy and enhance the comfort of patients who may be able to receive treatment at home."

Although this research yielded promising results in an animal model, it has not yet been proven effective in humans, which prompted scientists to establish the startup Imescia, and they hope to start clinical trials in 2024.

Follow our latest local and sports news and the latest political and economic developments via Google news